Navigation Links
CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus

HOUSTON--(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. (CYGX.OB) announced today that it has successfully completed an important pilot study with a novel synDNA(TM) vaccine designed for humans (therapeutic) and intended to protect against the avian (H5N1) influenza virus. The study clearly demonstrated a robust protective effect in mice treated with the Company's synDNA(TM) vaccine whereas all the untreated control animals died after both groups were challenged with a highly virulent strain of avian influenza virus (Vietnam/1203/04). The lethal challenge testing was conducted by recognized collaborators in the field under a sponsored research agreement with the Company.

The complete results from this study and related tests of synDNA(TM) vaccines will be presented at the 2007 DNA Vaccine conference to be held 23-25 May 2007 in Malaga, Spain.

Dr. Yin Chen, Chief Scientific Officer, stated, "This novel DNA vaccine was produced using a unique combination of novel gene sequences and our proprietary synDNA(TM) production technology. We are extremely excited about this initial robust response in an animal challenge model."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA(TM) production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside the cell. CytoGenix currently holds 11 granted patents and about 36 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release ar e forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

Contact

CytoGenix, Inc., Houston
Media Contact:
Pam Schertz, 713-789-0070


'"/>




Related medicine technology :

1. CytoGenix to Present at 2007 International DNA Vaccines Conference in Spain
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 11, 2016 ... of the "Molecular Diagnostics Reports Bundle" ... http://www.researchandmarkets.com/research/rp4pg8/molecular ) has announced the addition ... report to their offering. --> ... has announced the addition of the ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
(Date:2/10/2016)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... quarter and full year ended December 31, 2015. ... a transformational year for Vanda with the continued growth ... approval of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, ... to our U.S. product portfolio builds on this success ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... The ... candidates for the Board of Commissioners. Individuals interested in volunteer board service are ... diversity of clinical practice settings and across allied health to contribute to its ...
(Date:2/11/2016)... SURPRISE, ARIZ. (PRWEB) , ... February 11, 2016 , ... ... kids,” a group of men, 60 and older, who gather once a year to ... , Besides a love for the game, the more than 50 players who competed ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. ... Infusion Therapy Standards of Practice, to include vascular visualization as a standard practice. ... 85% share of the market, facilitates adherence to this standard with its easy ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dickinson Insurance & Financial Services ... a new fundraiser in support of a local boy named Barrett, who has been ... bring awareness to, and rally support for, all local families dealing with childhood cancer. ...
(Date:2/11/2016)... ... ... Be Well Medical Group (Be Well) is pleased to announce the ... Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a concierge practice ... their homes, offices or at the practices’ local office. It is also one of ...
Breaking Medicine News(10 mins):